Mon, Sep 1, 2014, 6:23 PM EDT - U.S. Markets closed for Labor Day

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

jdperezsr 26 posts  |  Last Activity: Aug 28, 2014 5:59 PM Member since: Jun 26, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • it is almost guaranteed that they are trying to get the stock price up to do a secondary. I hung in as long as I could but took my losses and sold. I obviously will be listening to what they have to say but I wont come back in until they have turned the corner.

    Sentiment: Hold

  • AAPL is hush hush about any details they give out and I am sure when this deal was made AAPL told GTAT you WILL do what we do. So sour grape analysts do what they do to AAPL....downgrades. I can't wait to see GTAT blow out the expectations. Hold tight longs and keep some powder for any real dips.

    Sentiment: Strong Buy

  • jdperezsr jdperezsr Aug 26, 2014 9:16 PM Flag

    I am basing the buy on a merger and/or an equity share agreement going forward as a settlement. PIP knows they can't pay and its in their best interest to something along these lines.

    Sentiment: Buy

  • when in fact they want out anything below 74 so they want you to feel "good enough" to sell at 71, 72 or 73. They will say "I am taking my money now and making it work somewhere else" or "this thing will trade 5% to 10% below offer price." FK them.....hold your shares till the merger is complete. Or sell above 74 if that suits you but to sell below 74 just gives them a way out.

    Sentiment: Hold

  • managements decision to hold out when this went to court. All the SA articles that were finely crafted to make investors think there was no way Siga could lose. Now that Siga has lost everyone including Siga is crying fowl. Greed got the worst of Siga and even more so for the investors. I still see this last hold out of investors saying this will all be overturned or that Siga won't have to pay much. Wrong move again. Siga needs to settle on the high end and then collaborate going forward as part of the settlement. That IMO would be acceptable to Pip and their investors.

  • jdperezsr jdperezsr Aug 11, 2014 8:11 PM Flag

    I am guessing now that this decision is in that we will see a settlement on the high side between the two of them so this doesn't drag on. I say buy both at these levels. I did. JMO

    Sentiment: Strong Buy

  • and with the appeal hanging over us we will sit around these levels until close to decision.

    Sentiment: Strong Buy

  • Reply to

    Courts favored remedy for establishing Damages

    by jdperezsr Aug 10, 2014 1:50 PM
    jdperezsr jdperezsr Aug 11, 2014 1:06 AM Flag

    read the order...better yet, read Sigas own press release. The math is in my postings taken directly from the court order.

    Sentiment: Strong Buy

  • I find that PharmAthene has proven by a preponderance of the evidence that Baliban‟s assumption that PharmAthene could expect to sell ST-246 for $100 per course to the U.S. government was reasonable at the time of the breach.64 Baliban made an independent assessment of the parties‟ assumption of a $100 per course price in their license agreement negotiations by analyzing examples of the U.S. government‟s purchase of pharmaceutical countermeasures.65 This assessment revealed that the $100 per course figure comported with the government‟s prior purchases. It also is significant that the contract BARDA entered into with SIGA in 2011 to purchase ST-246 requires the government to pay significantly more than $100 per course. In sum, I have determined that PharmAthene has proven sufficiently the quantity of ST-246 sales it reasonably expected to enjoy as its initial sale at the time of SIGA‟s breach. That quantity is 14,903,245 courses, which consists of 14,778,000 in sales to the U.S. SNS and 125,245 courses in sales to the DoD.

    Sentiment: Strong Buy

  • All of those facts are in addition to SIGA‟s own conduct and beliefs in late 2006 that ultimately contributed to its breach in December 2006. By late 2005, SIGA valued ST-246 conservatively at approximately $1 billion.60 In mid-to-late 2006, as ST-246 began to look “more and more like a multi-billion dollar drug,” SIGA began experiencing “seller‟s remorse,” which was the primary impetus for its bad faith conduct later.61 Thus, at the time of SIGA‟s breach, PharmAthene was not alone in reasonably believing that ST-246 imminently would be commercialized (with great success). SIGA, the company that then was in control of the drug and had unique insights into its development and prospects, had a similar, if not identical, outlook for the drug. I conclude, therefore, that, as of December 2006, ST-246 objectively had a very high likelihood of being commercialized in the near future via sales to the SNS, and that Baliban‟s use of an 84% “probability of success” factor was both reasonable and supported by the evidence. These facts, among others, persuade me that, at the time of the breach, PharmAthene had a reasonable expectation that the U.S. government would begin purchasing ST-246 for the SNS62 within four years, i.e., by 2010, at the latest. I adopt, therefore, 2010 as the year in which ST-246 sales to the U.S. government reasonably would have been expected to begin as of December 2006. Consequently, Baliban should have used 2010 as the commencement date for sales of ST-246 to the U.S. government rather than the more aggressive 2008 date.

    Sentiment: Strong Buy

  • “This principle of expectation damages is measured by the amount of money that would put the promisee in the same position as if the promisor had performed the contract.”35 One measure of expectation damages is a party‟s lost profits. An award of lost profits, however, like any expectation damages award, “presupposes that the plaintiff can prove damages with reasonable certainty.”
    The issue then becomes what does it mean to be able to prove damages with reasonable certainty? “Responsible estimates of damages that lack mathematical certainty are permissible so long as the court has a basis to make such a responsible estimate.” To support its claim that it is entitled to an award of expectation damages for SIGA‟s bad faith breach of its contractual obligations, PharmAthene offered the expert report and testimony at trial of Jeffrey L. Baliban.44 In his report, Baliban presented damages calculations for six different scenarios using the discounted future earnings method. Of those six, I find most relevant the one in which Baliban calculated PharmAthene‟s damages according to the terms of the LATS based on facts that purportedly were known as of December 20, 2006 (the “Basis 1 LATS Scenario”).45 Using that scenario, Baliban calculated PharmAthene‟s expectation damages to be $1.07 billion.

    Sentiment: Strong Buy

  • Had SIGA and PharmAthene actually consummated a license agreement in accordance with the LATS, that agreement would have entrusted PharmAthene with the primary responsibility for developing ST-246. One of the most significant consequences of SIGA‟s bad faith breach of its obligation to negotiate a license agreement in good faith is that up until today, SIGA, not PharmAthene, has controlled the development of ST-246. PharmAthene legitimately can claim to have suffered serious damage from being deprived wrongfully of the opportunity to control development of a promising drug such as ST-246. At the same time, as compared to the parties‟ presumed license agreement, SIGA has expended significantly more time and resources to develop ST-246 than the two sides had contemplated, and PharmAthene has expended significantly less. Accordingly, ordering SIGA to transfer control of ST-246 to PharmAthene now, and allowing PharmAthene to enjoy the fruits of SIGA‟s labors in developing ST-246 without undertaking most of the obligations that were expected of it, would result in the enforcement of a drastically different agreement than the one SIGA and PharmAthene actually contemplated.
    Therefore, PharmAthene has two potential remedies available to it in this remand proceeding: (1) lump sum expectation damages; and (2) an equitable payment stream based on the terms of the LATS.29 I turn next to an analysis of the merits of those respective potential damages awards. the Supreme Court stated definitively that expectation damages potentially could be awarded for SIGA‟s bad faith conduct. In the same vein, the Supreme Court also emphasized the central role of the contract as the source of any remedy I could award for SIGA‟s breach. Under Delaware law, the standard remedy for breach of contract is based on the reasonable expectations of the parties that existed before or at time of the breach.

    Sentiment: Strong Buy

  • is left to give the earnings report while everyone else is shreading and running for the doors while the stock goes to zero! LMAO

  • Reply to

    So, The Question is....,

    by trumpace Aug 7, 2014 10:03 AM
    jdperezsr jdperezsr Aug 7, 2014 4:27 PM Flag

    Good call Trump....i have been holding shares for sometime because I don't need the money but now I am thinking I could have had that money working better somewhere else. They deserve to get hammered for this BS

    Sentiment: Sell

  • If you review last quartr they Shipped 42K and recognized 39K with a deferral of 290K. This quarter thy beat by a penny (street expected -.08) they did -.07 and the deferred 300, shipped 53K and recognize 35k. The real news the market wants is the partnership for the oxyxodone. Mybe sme news on the conference call. Lets see.

    Sentiment: Hold

  • jdperezsr jdperezsr Aug 4, 2014 5:40 PM Flag

    Actually Mitch the Nexafed was a bit better his quarter than last. If you review last quartr they Shipped 42K and recognized 39K with a deferral of 290K. This quarter thy beat by a penny (street expected -.08) they did -.07 and the deferred 300, shipped 53K and recognize 35k. The real news the market wants is the partnership for the oxyxodone. Mybe sme news on the conference call. Lets see.

    Sentiment: Hold

  • one way or another. These guys could take a lesson from QCOR and protect your turf. Anytime you remain silent then the street will assume the worst and this is what you get. Amatures in training as far as I am concerned. Congrats to the shorts. It's been hard for them lately.

    Sentiment: Sell

  • Reply to

    How about some results?

    by mountainmansmith May 22, 2014 8:21 AM
    jdperezsr jdperezsr Jul 2, 2014 9:09 AM Flag

    Just checking back in...this stock is easy to figure out. Any run up you short. The only thing that will change this is meaningful sales. As you can tell there are no news releases about that. They just release fluff and hope you won't look at their SEC filings.

  • Reply to

    stupid move of the day

    by maxamaddie Jun 30, 2014 3:32 PM
    jdperezsr jdperezsr Jul 1, 2014 11:05 AM Flag

    Thx L2L. Appreciate the heads up

  • Reply to

    stupid move of the day

    by maxamaddie Jun 30, 2014 3:32 PM
    jdperezsr jdperezsr Jul 1, 2014 9:24 AM Flag

    L2L do you trade in and out of TZA or are you holding TZA?

SGEN
44.01+0.44(+1.01%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Criteo SA
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Yahoo! Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT